

Status: Currently Official on 17-Feb-2025
Official Date: Official as of 01-Dec-2016
Document Type: USP Monographs
DocId: GUID-1BB8F063-884A-4921-A25F-0AD404914611_1_en-US
DOI: https://doi.org/10.31003/USPNF_M1801_01_01
DOI Ref: pjx2v

© 2025 USPC
Do not distribute

Tramadol Hydrochloride Compounded Oral Suspension

DEFINITION

Tramadol Hydrochloride Compounded Oral Suspension contains NLT 90.0% and NMT 110.0% of the labeled amount of tramadol hydrochloride ($C_{16}H_{25}NO_2 \cdot HCl$).

Prepare Tramadol Hydrochloride Compounded Oral Suspension 5 mg/mL as follows (see [Pharmaceutical Compounding—Nonsterile Preparations \(795\)](#)).

| | |
|--|----------------------------------|
| Tramadol Hydrochloride tablets ^a equivalent to | 500 mg of tramadol hydrochloride |
| Vehicle: a 1:1 mixture of Ora-Sweet ^b (sugar-free) and Ora-Plus, ^b a sufficient quantity to make | 100 mL |

^a Ultram 50-mg tablets, Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ.

^b Paddock Laboratories, Minneapolis, MN.

Calculate the required quantity of each ingredient for the total amount to be prepared. Place the required number of *Tramadol Hydrochloride tablets* in a suitable mortar, and comminute to a fine powder. Add the *Vehicle* in small portions, and triturate to make a smooth paste. Add increasing volumes of the *Vehicle* to make a tramadol hydrochloride liquid that is pourable. Transfer the contents of the mortar, stepwise and quantitatively, to a calibrated bottle. Add enough of the *Vehicle* to bring to final volume, and mix well.

ASSAY

• PROCEDURE

Solution A: 20 mM of phosphoric acid and 4 g/L of sodium 1-hexane sulfonate

Mobile phase: Acetonitrile and *Solution A* (50:50). Filter and degas.

Diluent: Acetonitrile and water (50:50)

Standard solution: 0.25 mg/mL of [USP Tramadol Hydrochloride RS](#) in *Diluent*

Sample solution: Shake thoroughly by hand each bottle of Oral Suspension. Prepare 0.25 mg/mL of tramadol hydrochloride from Oral Suspension and *Diluent*, and centrifuge.

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 275 nm

Column: 4.6-mm × 25-cm; 5-μm packing L1

Column temperature: 30°

Flow rate: 1.0 mL/min

Injection volume: 5 μL

System suitability

Sample: *Standard solution*

[NOTE—The retention time for tramadol hydrochloride is about 6 min.]

Suitability requirements

Relative standard deviation: NMT 2.0% for replicate injections

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of tramadol hydrochloride ($C_{16}H_{25}NO_2 \cdot HCl$) in the portion of Oral Suspension taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_u = peak response from the *Sample solution*

r_s = peak response from the *Standard solution*

C_s = concentration of [USP Tramadol Hydrochloride RS](#) in the *Standard solution* (mg/mL)

C_u = nominal concentration of tramadol hydrochloride in the *Sample solution* (mg/mL)

Acceptance criteria: 90.0%–110.0%

SPECIFIC TESTS

- [pH \(791\)](#): 3.8–4.8

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Package in tight, light-resistant containers. Store in a refrigerator or at controlled room temperature.
- **Beyond-Use Date:** NMT 90 days after the date on which it was compounded when stored in a refrigerator or controlled room temperature
- **LABELING:** Label it to indicate that it is to be well shaken before use, and to state the *Beyond-Use Date*.
- [USP Reference Standards \(11\)](#)
[USP Tramadol Hydrochloride RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

| Topic/Question | Contact | Expert Committee |
|---|---|--------------------------|
| TRAMADOL HYDROCHLORIDE COMPOUNDED ORAL SUSPENSION | Brian Serumaga Science Program Manager | CMP2020 Compounding 2020 |
| REFERENCE STANDARD SUPPORT | RS Technical Services RSTECH@usp.org | CMP2020 Compounding 2020 |

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 41(1)

Current DocID: [GUID-1BB8F063-884A-4921-A25F-0AD404914611_1_en-US](#)

DOI: https://doi.org/10.31003/USPNF_M1801_01_01

DOI ref: [pjx2v](#)